David J. Moliterno

Learn More
WRITING COMMITTEE MEMBERS Vallerie V. McLaughlin, MD, FACC, FAHA, FCCP, Chair*; Stephen L. Archer, MD, FACC, FAHA†; David B. Badesch, MD, FCCP‡; Robyn J. Barst, MD, FACC, FAHA, FCCP†; Harrison W. Farber, MD, FAHA, FCCP†; Jonathan R. Lindner, MD, FACC; Michael A. Mathier, MD, FACC*; Michael D. McGoon, MD, FACC, FCCP§; Myung H. Park, MD, FACC*; Robert S.(More)
BACKGROUND Vorapaxar is a new oral protease-activated-receptor 1 (PAR-1) antagonist that inhibits thrombin-induced platelet activation. METHODS In this multinational, double-blind, randomized trial, we compared vorapaxar with placebo in 12,944 patients who had acute coronary syndromes without ST-segment elevation. The primary end point was a composite of(More)
Dual antiplatelet therapy with aspirin and a thienopyridine has been shown to reduce cardiac events after coronary stenting. However, many patients and healthcare providers prematurely discontinue dual antiplatelet therapy, which greatly increases the risk of stent thrombosis, myocardial infarction, and death. This advisory stresses the importance of 12(More)
BACKGROUND An antithrombotic drug is needed that safely reduces cardiovascular events in patients undergoing percutaneous coronary intervention (PCI). We therefore assessed the tolerability and safety of SCH 530348-an oral platelet protease-activated receptor-1 antagonist. METHODS We randomly assigned patients aged 45 years or older and undergoing(More)
CONTEXT It is unclear if blood transfusion in anemic patients with acute coronary syndromes is associated with improved survival. OBJECTIVE To determine the association between blood transfusion and mortality among patients with acute coronary syndromes who develop bleeding, anemia, or both during their hospital course. DESIGN, SETTING, AND PATIENTS We(More)
ACCF Task Force Members: Robert A. Harrington, M.D., F.A.C.C. Chair, Eric R. Bates, M.D., F.A.C.C., Charles R. Bridges, M.D., M.P.H., F.A.C.C., Mark J. Eisenberg, M.D., M.P.H., F.A.C.C., Victor A. Ferrari, M.D., F.A.C.C., Mark A. Hlatky, M.D., F.A.C.C., Sanjay Kaul, M.B.B.S., F.A.C.C., Jonathan R. Lindner, M.D., F.A.C.C.3 David J. Moliterno, M.D., F.A.C.C.,(More)
BACKGROUND Diabetes mellitus is a major risk factor for adverse outcomes after acute coronary syndromes (ACS). Because this disease may be associated with increased platelet aggregation, we investigated whether diabetic patients with ACS derive particular benefit from platelet glycoprotein (GP) IIb/IIIa receptor inhibition. METHODS AND RESULTS We(More)
OBJECTIVES This study sought to evaluate ischemic and bleeding outcomes in patients with chronic kidney disease (CKD) undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES). BACKGROUND Previous studies have shown that CKD is associated with poor outcomes after PCI. However, these studies were largely conducted before the(More)